Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis and the immune system. The company pipeline includes novel product candidates that leverage understanding of the tumor microenvironement, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with its proprietary drug candidates as long as continued development is supported by clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
To learn more, visit www.compasstherapeutics.com
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $312M
Founded date: 2014
Investors 6
Date | Name | Website |
06.03.2022 | Foresite C... | foresiteca... |
- | F-Prime Ca... | fprimecapi... |
- | OrbiMed | orbimed.co... |
- | Montrose C... | montroseca... |
- | Eight Road... | eightroads... |
- | GV | gv.com |
Funding Rounds 3
Date | Series | Amount | Investors |
24.06.2020 | - | $60M | - |
12.07.2018 | Series A | $132M | - |
08.07.2015 | - | $120M | - |
Mentions in press and media 17
Date | Title | Description | Source |
19.01.2023 | Compass Therapeutics Announces that the Phase 2 Data of CTX-... | /EIN News/ -- Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combina... | einpresswi... |
05.03.2021 | Compass Therapeutics Reports Fourth Quarter and Full Year 20... | BOSTON--(BUSINESS WIRE)--Mar 5, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage b... | oaoa.com/n... |
04.03.2021 | Compass Therapeutics to Commence Trading on the OTCQB Ventur... | BOSTON--(BUSINESS WIRE)--Mar 4, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage b... | oaoa.com/n... |
24.06.2020 | Compass Therapeutics Completes Reverse Merger and Closes $60... | - | fprimecapi... |
23.06.2020 | Compass Therapeutics Completes Reverse Merger and Closes $60... | - | orbimed.co... |
13.07.2018 | Term Sheet – Friday, July 13 | EDUCATION Happy Friday. Polina returns Monday. Reach me lucinda.shen@fortune.com. Paid Content Sec... | fortune.co... |
12.07.2018 | Compass Therapeutics Closes on Series A Financing Totaling $... | - | fprimecapi... |
12.07.2018 | Compass Therapeutics launches with $132M to advance a clutch... | Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in pr... | fiercebiot... |
12.07.2018 | Compass Therapeutics Completes $132M Series A Financing | Compass Therapeutics, a Cambridge, MA-based biotechnology company committed to comprehensively drugg... | finsmes.co... |
12.07.2018 | Compass Therapeutics launches with $132M to advance a clutch... | Compass Therapeutics is coming out of stealth with $132 million in series A cash, 15 prospects in pr... | fiercebiot... |
Show more